🚀 VC round data is live in beta, check it out!
CytoDyn Valuation Multiples
Discover revenue and EBITDA valuation multiples for CytoDyn and similar public comparables like Aldeyra Therapeutics, Akebia Therapeutics, Celon Pharma, Cabaletta Bio and more.
CytoDyn Overview
About CytoDyn
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
Founded
2002
HQ
Employees
13
Website
Sectors
Financials (FY)
EV
$335M
CytoDyn Financials
CytoDyn reported last fiscal year revenue of — and EBITDA of $9M.
In the same fiscal year, CytoDyn generated $9M in EBITDA and $4M in net income.
Revenue (LTM)
CytoDyn P&L
In the most recent fiscal year, CytoDyn reported revenue of — and EBITDA of $9M.
CytoDyn expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | $9M | XXX | XXX | XXX |
| Net Profit | — | XXX | $4M | XXX | XXX | XXX |
| Net Debt | — | — | $15M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
CytoDyn Stock Performance
CytoDyn has current market cap of $313M, and enterprise value of $335M.
Market Cap Evolution
CytoDyn's stock price is $0.25.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $335M | $313M | 0.0% | XXX | XXX | XXX | $0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCytoDyn Valuation Multiples
CytoDyn trades at 39.0x EV/EBITDA.
EV / Revenue (LTM)
CytoDyn Financial Valuation Multiples
As of March 21, 2026, CytoDyn has market cap of $313M and EV of $335M.
Equity research analysts estimate CytoDyn's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CytoDyn has a P/E ratio of 83.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $313M | XXX | $313M | XXX | XXX | XXX |
| EV (current) | $335M | XXX | $335M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 39.0x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 34.7x | XXX | XXX | XXX |
| P/E | — | XXX | 83.5x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (38.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified CytoDyn Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
CytoDyn Margins & Growth Rates
CytoDyn's revenue in the last fiscal year grew by —.
CytoDyn Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (164%) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
CytoDyn Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Aldeyra Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Akebia Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Celon Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Cabaletta Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Protara Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CytoDyn M&A Activity
CytoDyn acquired XXX companies to date.
Last acquisition by CytoDyn was on XXXXXXXX, XXXXX. CytoDyn acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by CytoDyn
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCytoDyn Investment Activity
CytoDyn invested in XXX companies to date.
CytoDyn made its latest investment on XXXXXXXX, XXXXX. CytoDyn invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by CytoDyn
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout CytoDyn
| When was CytoDyn founded? | CytoDyn was founded in 2002. |
| Where is CytoDyn headquartered? | CytoDyn is headquartered in United States. |
| How many employees does CytoDyn have? | As of today, CytoDyn has over 13 employees. |
| Is CytoDyn publicly listed? | Yes, CytoDyn is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of CytoDyn? | CytoDyn trades under CYDY ticker. |
| When did CytoDyn go public? | CytoDyn went public in 2005. |
| Who are competitors of CytoDyn? | CytoDyn main competitors are Aldeyra Therapeutics, Akebia Therapeutics, Celon Pharma, Cabaletta Bio. |
| What is the current market cap of CytoDyn? | CytoDyn's current market cap is $313M. |
| Is CytoDyn profitable? | No, CytoDyn is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.